Nanosonics Ltd (ASX: NAN) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Nanosonics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $947.86 million
P/E Ratio 47.61
Dividend Yield 0.00%
Shares Outstanding 302.83 million
Earnings per share 0.065
Dividend per share N/A
Year To Date Return -29.77%
Earnings Yield 2.10%
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Nanosonics Ltd (ASX: NAN)
    Latest News

    Three hikers lift their arms in jubilation as they reach a rocky peak overlooking a sensational view of water and mountains with a blue sky surrounding them.
    Share Market News

    Here are the top 10 ASX 200 shares today

    The ASX 200 finished up the week on a high this Thursday...

    Read more »

    Three guys in shirts and ties give the thumbs down.
    Share Fallers

    Why Adriatic Metals, Chrysos, Coronado, and Nanosonics shares sinking today

    These ASX shares are having a poor session. Why are investors selling them?

    Read more »

    A man holds his head in his hands, despairing at the bad result he's reading on his computer.
    Healthcare Shares

    Here's why Nanosonics shares are crashing 37% today

    What's going on with this popular stock on Wednesday?

    Read more »

    Five happy young friends on the coast, dabbing and raising their arms in the air.
    Share Market News

    Here are the top 10 ASX 200 shares today

    The ASX 200 ended the trading week on a high today...

    Read more »

    A man sits thoughtfully on the couch with a laptop on his lap.

    The top 10 ASX shares I'm picking for a prosperous 2024

    I've trawled through hundreds of Australian stocks to find 10 that I think could be the bee's knees in 2024.

    Read more »

    Top 10 blank list on chalkboard
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was back to reality for ASX shares today...

    Read more »

    Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
    Share Market News

    Here are the top 10 ASX 200 shares today

    The ASX's stellar November run came to an end today.

    Read more »

    A senior couple discusses a share trade they are making on a laptop computer
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was another horror show on the ASX 200 today.

    Read more »

    Top ten gold trophy.
    Share Market News

    Here are the top 10 ASX 200 shares today

    The ASX 200 lost even more ground today in a nasty session.

    Read more »

    A woman faces away from the camera as she stand on the beach with an Australian flag around her shoulders and making a heart shape with her hands.
    Broker Notes

    Advance Australia fair: 2 ASX 200 shares leveraging the Aussie advantage

    Expert names two quality Australian companies that haven't yet been fully appreciated by the market.

    Read more »

    A dog looks confused and a little sad, indicating a dip in share price movement

    3 underdogs on my ASX watchlist after being punished in August

    I think the market might have overreacted to the results of these companies. Here's why I'll be watching them more…

    Read more »

    a group of people in business attire gather around a computer in an office environment with expressions of concern as they try to nut out the answer to a challenge they are facing.
    Broker Notes

    7 ASX 200 shares upgraded by brokers following earnings updates

    Which seven ASX 200 companies have received a positive broker re-rating?

    Read more »

    Frequently Asked Questions

    No, Nanosonics Ltd does not pay dividends at this stage.

    Nanosonics Ltd listed on the ASX on 17 May 2007.

    NAN ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Nanosonics Ltd

    Nanosonics Ltd (ASX: NAN) is an Australian healthcare company specialising in infection prevention.

    The company has developed and commercialised an automated disinfection technology, the trophon device. Nanosonics says it represents the first major innovation in high-level disinfection for ultrasound probes in more than two decades and is fast becoming the global standard of care for ultrasound probe disinfection. The company also manufactures and distributes other related technologies.

    Nanosonics is based in Sydney with sales offices in the US and Europe.

    NAN Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    23 Feb 2024 $3.13 $0.04 1.29% 966,950 $3.08 $3.17 $3.03
    22 Feb 2024 $3.09 $0.10 3.34% 986,266 $2.99 $3.13 $2.98
    21 Feb 2024 $2.99 $-0.01 -0.33% 1,228,416 $2.99 $3.03 $2.99
    20 Feb 2024 $3.00 $0.00 0.00% 477,510 $3.00 $3.04 $2.95
    19 Feb 2024 $3.00 $0.02 0.67% 602,908 $2.99 $3.04 $2.94
    16 Feb 2024 $2.98 $-0.02 -0.67% 583,069 $3.01 $3.03 $2.97
    15 Feb 2024 $3.00 $0.08 2.74% 883,827 $2.92 $3.01 $2.91
    14 Feb 2024 $2.92 $0.01 0.34% 498,477 $2.89 $2.93 $2.89
    13 Feb 2024 $2.91 $-0.01 -0.34% 674,518 $2.93 $2.94 $2.89
    12 Feb 2024 $2.92 $-0.02 -0.68% 679,142 $2.94 $3.00 $2.91
    09 Feb 2024 $2.94 $-0.02 -0.68% 633,313 $2.96 $2.97 $2.91
    08 Feb 2024 $2.96 $-0.03 -1.00% 476,923 $2.99 $3.01 $2.93
    07 Feb 2024 $2.99 $0.10 3.46% 921,421 $2.91 $3.01 $2.91
    06 Feb 2024 $2.89 $-0.06 -2.03% 847,819 $2.91 $2.97 $2.87
    05 Feb 2024 $2.95 $0.00 0.00% 618,311 $2.92 $2.99 $2.91
    02 Feb 2024 $2.95 $0.05 1.72% 1,045,747 $2.93 $2.95 $2.89
    01 Feb 2024 $2.90 $-0.08 -2.68% 1,558,823 $2.92 $2.98 $2.89
    31 Jan 2024 $2.98 $0.04 1.36% 2,996,294 $2.91 $2.98 $2.88
    30 Jan 2024 $2.94 $-0.03 -1.01% 1,404,682 $2.96 $2.99 $2.90
    29 Jan 2024 $2.97 $-0.07 -2.30% 1,811,720 $3.04 $3.10 $2.88
    25 Jan 2024 $3.04 $0.13 4.47% 3,588,254 $2.94 $3.15 $2.91

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    03 Oct 2023 Michael Kavanagh Expiry 286,551 $1,154,800
    As advised by the company. 9,77,130 Performance Rights & Service Rights, lapsed
    29 Aug 2023 Michael Kavanagh Buy 150,479 $619,973
    Exercise of options.
    29 Aug 2023 Michael Kavanagh Exercise 340,424 $1,402,546
    Exercise of options.
    08 Jun 2023 Michael Kavanagh Sell 25,000 $120,732
    On-market trade.
    08 Mar 2023 David Fisher Sell 110,000 $503,937
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Lisa Margaret McIntyre Non-Executive Director Dec 2019
    Dr McIntyre background is in strategy, particularly in the areas of medical technology and healthcare, with many years as a partner at L.E.K. Consulting in the US and Australia, where she led the Asia Pacific Health practice. Dr. McIntyre was a Director of the Garvan Institute of Medical Research for 12 years and is a Senate Fellow of the University of Sydney. She is currently a Non-executive Director of Fisher and Paykel Healthcare Corporation Limited, HCF Group, HCF Life, HCF Foundation, and Studiosity Pty Ltd. She is member of the Risk Committee and Chair of the R&D and Innovation Committee from 1st January 2023.
    Mr David Fisher Non-Executive Director Jul 2001
    Mr is a founding partner of Brandon Capital Partners, an Australian venture capital provider. Dr Fisher has more than 35 years of operating experience in the biotechnology and healthcare industry in Australia and overseas. He held senior positions with Pharmacia AB (now part of Pfizer, Inc) and was CEO of Peptech Limited. He has not held any directorships of other listed companies in the last three years. He is member of the Risk Committee and Chair of R&D and Innovation Committee till 1st January 2023.
    Dr Larry Marshall Non-Executive Director Oct 2023
    Dr Marshall brings experience to the Company. Dr Marshall is a technology innovator, physicist and business leader with over 30 years experience in leadership of technology companies. He has founded companies and innovation in Silicon Valley and Australia. Until July 2023, Dr Marshall was Chief Executive of CSIRO for 8 years. Dr Marshall lived in the United States for 26 years, where he co-founded 6 companies in a range of markets including medical device. Over the past 30 years he has served as CEO/MD of 6 companies, and Chairman of 4. He was MD, then co-Chairman of Arasor, a developer and manufacturer of integrated optical and wireless solutions, which he took public in 2006. In 2007, Dr Marshall became MD of Southern Cross Venture Partners, a Silicon Valley VC firm specialising in Australian innovation. He has been a director of 20 private sector boards in Australia and the United States, including boards of 2 companies that were subsequently listed on the Nasdaq and on the ASX respectively.
    Mr Michael Kavanagh Chief Executive OfficerManaging Director Jul 2012
    Mr Kavanagh has more than 29 years of international commercial experience in the healthcare market, having held local, regional, and global roles in medical device and pharmaceutical industries. Before joining Nanosonics, he was Senior Vice President of Global Marketing for the medical device company Cochlear Ltd, a position he held for more than 10 years. In the last three years Mr Kavanagh has held no other directorships.
    Ms Marie Elizabeth McDonald Non-Executive Director Oct 2016
    Ms McDonald has background in corporate and commercial law, having practiced for many years as a partner at Ashurst. Ms McDonald was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia (2012 to 2013) and was a member of the Australian Takeovers Panel from 2001 to 2010. She is member of Risk Committee.
    Mr Steven Andrew Sargent Non-Executive DirectorNon-Executive Chairman Jul 2016
    Mr Sargent had a 22-year career with General Electric and has global experience across a range of industries, including financial services and healthcare. He was Vice President and Officer of GE, a member of GE's Corporate Executive Council and CEO of GE Australia NZ. He is also member of the Risk and R&D and Innovation Committee.
    Dr Tracey Leigh Batten Non-Executive Director Sep 2023
    Dr Batten has experience of more than 30 years. During her executive career, Dr Batten was Group CEO of Imperial College Healthcare NHS Trust in the United Kingdom, Group CEO of St Vincents Health Australia, CEO of Eastern Health, CEO of Dental Health Services Victoria and held various other clinical and medical leadership roles. Dr Batten is currently a non-executive director of Medibank Private Ltd, the EBOS Group Limited (NZX Listed), the Accident Compensation Corporation (a NZ Crown insurance scheme and investment fund) and the National Institute of Water and Atmospheric Research (a NZ Crown Research Institute). In addition, Dr Batten was previously non-executive director of Abano Healthcare Group Ltd (NZX Listed) and various other healthcare related research institutes, charities and industry and government bodies.
    Mr Geoff Raymond Wilson Non-Executive Director Jul 2019
    Mr Wilson has local and international executive leadership and director experience together spanning more than 37 years, including many years with KPMG in Australia, Hong Kong, and the USA. He has a background in finance, audit, and risk management, as well as in the Asia Pacific markets. Mr Wilson is currently a Director of TOLL Holdings Limited, HSBC Bank Australia Limited, ipSCAPE, and Sydney Symphony Limited. He is also an Ambassador for the Australian Indigenous Education Foundation. He is Chair of Risk Committee.
    Mr Matthew Carbines General CounselCompany Secretary May 2023
    McGregor Grant Chief Financial Officer and Company Secretary
    Sunny Pillai Chief Information Officer
    Matthew Lipscombe Chief Marketing Officer
    Rod Lopez Chief Operating Officer
    Jodi Sampson Chief People and Culture Officer
    David Morris Chief Strategy Officer and Regional President Asia Pacific
    Steven Farrugia Chief Technology Officer
    Matthew Carbines General Counsel
    Matthew Carbines General CounselCompany Secretary
    Ronan Wright Regional President for Europe and Middle East
    Ken Shaw Regional President for North America

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 61,767,191 20.43%
    Citicorp Nominees Pty Limited 44,181,499 14.61%
    J P Morgan Nominees Australia Pty Limited 38,356,423 12.69%
    BNP Paribas Noms Pty Ltd <Drp> 19,483,665 6.44%
    UBS Nominees Pty Ltd 11,561,555 3.82%
    National Nominees Limited 8,604,841 2.85%
    Mr Maurie Stang 8,129,534 2.69%
    Mr Bernard Stang 6,842,564 2.26%
    Mr Steve Kritzler 6,489,737 2.15%
    Australian Foundation Investment Company Limited 5,853,333 1.94%
    BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 4,535,691 1.50%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 4,227,938 1.40%
    Dr Harry Hirschowitz 2,139,090 0.71%
    First Samuel Ltd <ANF ITS MDA CLIENTS A/C> 1,483,891 0.49%
    Mirrabooka Investments Limited 1,335,007 0.44%
    Colonial First State Inv Ltd <2349414 Hofbauer A/C> 1,200,000 0.40%
    BNP Paribas Noms (NZ) LTD <DRP> 1,048,517 0.35%
    BNP Paribas Nominees Pty Ltd HUB24 Custodial Serv Ltd <Drp A/C> 999,603 0.33%
    Invia Custodian Pty Limited <Penance A/C> 950,000 0.31%
    Netwealth Investments Limited <Wrap Services A/C> 906,627 0.29%